Cite
MLA Citation
Paul J Cacciottolo et al.. “Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study.” BMJ open, vol. 11, no. 4, 2021, p. . http://access.bl.uk/ark:/81055/vdc_100127566989.0x000059